Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 3 - Caught on Camera

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA).

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

What to Expect From Moderna's Next Quarterly Earnings Report

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

inkl

Read news from The Economist, FT, and more,
with one subscription

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Moderna Stock Looks Ripe for a Short Squeeze

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Moderna Stock: Analyst Estimates & Ratings

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

What to Expect From Moderna's Q1 2025 Earnings Report

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

MarketBeat Week in Review – 03/10 - 03/14

Stocks continued to be under pressure on concerns over tariffs and growing inflation concerns, but history shows that corrections can set up opportunities

Get all your
news in one place.

100's of premium titles.
One news app.

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Get all your
news in one place.

100's of premium titles.
One news app.

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

International Business Times UK

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

Stock Market Today: Stocks Are Mixed Ahead of the Fed

Two of the three main equity indexes closed higher on the first day of the final Fed Week of 2024.

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

1 2 3 4 5

People

211,700 stories

Robert F. Kennedy Jr

Gabriel OsorioMazilli

Stephane Bancel

Stéphane Bancel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,123 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play